Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

The Damaging Effect of Passenger Mutations on Cancer Progression.

McFarland CD, Yaglom JA, Wojtkowiak JW, Scott JG, Morse DL, Sherman MY, Mirny LA.

Cancer Res. 2017 Sep 15;77(18):4763-4772. doi: 10.1158/0008-5472.CAN-15-3283-T. Epub 2017 May 23.

2.

Defining Cancer Subpopulations by Adaptive Strategies Rather Than Molecular Properties Provides Novel Insights into Intratumoral Evolution.

Ibrahim-Hashim A, Robertson-Tessi M, Enriquez-Navas PM, Damaghi M, Balagurunathan Y, Wojtkowiak JW, Russell S, Yoonseok K, Lloyd MC, Bui MM, Brown JS, Anderson ARA, Gillies RJ, Gatenby RA.

Cancer Res. 2017 May 1;77(9):2242-2254. doi: 10.1158/0008-5472.CAN-16-2844. Epub 2017 Mar 1.

3.

MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts.

Zhang X, Wojtkowiak JW, Martinez GV, Cornnell HH, Hart CP, Baker AF, Gillies R.

PLoS One. 2016 May 26;11(5):e0155289. doi: 10.1371/journal.pone.0155289. eCollection 2016.

4.

Cell-surface markers for colon adenoma and adenocarcinoma.

Sewda K, Coppola D, Enkemann S, Yue B, Kim J, Lopez AS, Wojtkowiak JW, Stark VE, Morse B, Shibata D, Vignesh S, Morse DL.

Oncotarget. 2016 Apr 5;7(14):17773-89. doi: 10.18632/oncotarget.7402.

5.

Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy.

Pilon-Thomas S, Kodumudi KN, El-Kenawi AE, Russell S, Weber AM, Luddy K, Damaghi M, Wojtkowiak JW, Mulé JJ, Ibrahim-Hashim A, Gillies RJ.

Cancer Res. 2016 Mar 15;76(6):1381-90. doi: 10.1158/0008-5472.CAN-15-1743. Epub 2015 Dec 30. Erratum in: Cancer Res. 2017 May 1;77(9):2552.

6.

Chronic acidosis in the tumour microenvironment selects for overexpression of LAMP2 in the plasma membrane.

Damaghi M, Tafreshi NK, Lloyd MC, Sprung R, Estrella V, Wojtkowiak JW, Morse DL, Koomen JM, Bui MM, Gatenby RA, Gillies RJ.

Nat Commun. 2015 Dec 10;6:8752. doi: 10.1038/ncomms9752.

7.

Application of Evolutionary Principles to Cancer Therapy.

Enriquez-Navas PM, Wojtkowiak JW, Gatenby RA.

Cancer Res. 2015 Nov 15;75(22):4675-80. doi: 10.1158/0008-5472.CAN-15-1337. Epub 2015 Nov 2. Review.

8.

Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302.

Wojtkowiak JW, Cornnell HC, Matsumoto S, Saito K, Takakusagi Y, Dutta P, Kim M, Zhang X, Leos R, Bailey KM, Martinez G, Lloyd MC, Weber C, Mitchell JB, Lynch RM, Baker AF, Gatenby RA, Rejniak KA, Hart C, Krishna MC, Gillies RJ.

Cancer Metab. 2015 Jan 29;3(1):2. doi: 10.1186/s40170-014-0026-z. eCollection 2015.

9.

Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer.

Bailey KM, Cornnell HH, Ibrahim-Hashim A, Wojtkowiak JW, Hart CP, Zhang X, Leos R, Martinez GV, Baker AF, Gillies RJ.

PLoS One. 2014 Dec 22;9(12):e113586. doi: 10.1371/journal.pone.0113586. eCollection 2014.

10.

Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302.

Takakusagi Y, Matsumoto S, Saito K, Matsuo M, Kishimoto S, Wojtkowiak JW, DeGraff W, Kesarwala AH, Choudhuri R, Devasahayam N, Subramanian S, Munasinghe JP, Gillies RJ, Mitchell JB, Hart CP, Krishna MC.

PLoS One. 2014 Sep 25;9(9):e107995. doi: 10.1371/journal.pone.0107995. eCollection 2014.

11.

Mechanisms of buffer therapy resistance.

Bailey KM, Wojtkowiak JW, Cornnell HH, Ribeiro MC, Balagurunathan Y, Hashim AI, Gillies RJ.

Neoplasia. 2014 Apr;16(4):354-64.e1-3. doi: 10.1016/j.neo.2014.04.005.

12.

pH sensing and regulation in cancer.

Damaghi M, Wojtkowiak JW, Gillies RJ.

Front Physiol. 2013 Dec 17;4:370. doi: 10.3389/fphys.2013.00370. Review.

13.

Acid-mediated tumor proteolysis: contribution of cysteine cathepsins.

Rothberg JM, Bailey KM, Wojtkowiak JW, Ben-Nun Y, Bogyo M, Weber E, Moin K, Blum G, Mattingly RR, Gillies RJ, Sloane BF.

Neoplasia. 2013 Oct;15(10):1125-37.

14.

Targeting the metabolic microenvironment of tumors.

Bailey KM, Wojtkowiak JW, Hashim AI, Gillies RJ.

Adv Pharmacol. 2012;65:63-107. doi: 10.1016/B978-0-12-397927-8.00004-X. Review.

15.

Autophagy on acid.

Wojtkowiak JW, Gillies RJ.

Autophagy. 2012 Nov;8(11):1688-9. doi: 10.4161/auto.21501. Epub 2012 Aug 9.

16.

Chronic autophagy is a cellular adaptation to tumor acidic pH microenvironments.

Wojtkowiak JW, Rothberg JM, Kumar V, Schramm KJ, Haller E, Proemsey JB, Lloyd MC, Sloane BF, Gillies RJ.

Cancer Res. 2012 Aug 15;72(16):3938-47. doi: 10.1158/0008-5472.CAN-11-3881. Epub 2012 Jun 19.

17.

Free Base Lysine Increases Survival and Reduces Metastasis in Prostate Cancer Model.

Ibrahim-Hashim A, Wojtkowiak JW, de Lourdes Coelho Ribeiro M, Estrella V, Bailey KM, Cornnell HH, Gatenby RA, Gillies RJ.

J Cancer Sci Ther. 2011 Nov 19;Suppl 1(4). pii: JCST-S1-004.

18.

Drug resistance and cellular adaptation to tumor acidic pH microenvironment.

Wojtkowiak JW, Verduzco D, Schramm KJ, Gillies RJ.

Mol Pharm. 2011 Dec 5;8(6):2032-8. doi: 10.1021/mp200292c. Epub 2011 Oct 26. Review.

19.

Imaging pH and metastasis.

Hashim AI, Zhang X, Wojtkowiak JW, Martinez GV, Gillies RJ.

NMR Biomed. 2011 Jul;24(6):582-91. doi: 10.1002/nbm.1644. Epub 2011 Mar 8. Review.

20.

Aborted autophagy and nonapoptotic death induced by farnesyl transferase inhibitor and lovastatin.

Wojtkowiak JW, Sane KM, Kleinman M, Sloane BF, Reiners JJ Jr, Mattingly RR.

J Pharmacol Exp Ther. 2011 Apr;337(1):65-74. doi: 10.1124/jpet.110.174573. Epub 2011 Jan 12.

21.

A novel geranylgeranyl transferase inhibitor in combination with lovastatin inhibits proliferation and induces autophagy in STS-26T MPNST cells.

Sane KM, Mynderse M, Lalonde DT, Dean IS, Wojtkowiak JW, Fouad F, Borch RF, Reiners JJ Jr, Gibbs RA, Mattingly RR.

J Pharmacol Exp Ther. 2010 Apr;333(1):23-33. doi: 10.1124/jpet.109.160192. Epub 2010 Jan 19.

22.

Working together: Farnesyl transferase inhibitors and statins block protein prenylation.

Wojtkowiak JW, Gibbs RA, Mattingly RR.

Mol Cell Pharmacol. 2009 Jan 1;1(1):1-6.

23.

Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.

Dilworth JT, Wojtkowiak JW, Mathieu P, Tainsky MA, Reiners JJ Jr, Mattingly RR, Hancock CN.

Cancer Biol Ther. 2008 Dec;7(12):1938-46. Epub 2008 Dec 7.

24.

Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.

Wojtkowiak JW, Fouad F, LaLonde DT, Kleinman MD, Gibbs RA, Reiners JJ Jr, Borch RF, Mattingly RR.

J Pharmacol Exp Ther. 2008 Jul;326(1):1-11. doi: 10.1124/jpet.107.135830. Epub 2008 Mar 26.

25.

Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1.

Dilworth JT, Kraniak JM, Wojtkowiak JW, Gibbs RA, Borch RF, Tainsky MA, Reiners JJ Jr, Mattingly RR.

Biochem Pharmacol. 2006 Nov 30;72(11):1485-92. Epub 2006 Apr 28. Review.

PMID:
16797490

Supplemental Content

Loading ...
Support Center